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EV-D68 Enterovirus D68
NPA Nasopharyngeal aspirate
[Abstract]
Enterovirus D68 (EV-D68) is an emerging infection associated with acute flaccid myelitis (AFM). 
Cases of AFM associated with EV-D68 infection have increased in recent years and the 
evidence for a causal link is growing. However, our understanding of the epidemiology, clinical 
features, prognosis, and neurological sequelae of EV-D68 requires ongoing surveillance and 
investigation. We report five cases of AFM in previously typically developing children (2–6y) 
from South East Scotland during September and October 2016 after infection with EV-D68 (all 
detected in the nasopharyngeal aspirates). All cases presented with significant neurological 
symptoms, which were severe in two cases requiring intensive care support because of 
respiratory paralysis. At 18 months follow-up, two cases remain ventilator-dependent with other 
cases requiring ongoing community rehabilitation. These cases represent one of the largest 
reported paediatric cluster of AFM associated with EV-D68 in Europe. The epidemiology and 
clinical information add to the knowledge base and the 18 months outcome will help clinicians to 
counsel families. 
What this paper adds:
 Nasopharyngeal aspirate is more sensitive for viral isolation and isolated in all cases.
 Clinical outcome at 18 months after enterovirus D68 with acute flaccid myelitis provides 
information on extent of recovery and level of disability. 
[First page footer]
(c) Mac Keith Press
DOI: 10.1111/dmcn.xxxxx
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[main text]
Acute flaccid myelitis (AFM) is a clinical syndrome, characterized by weakness in one or more 
limbs with or without respiratory and bulbar muscle weakness, with no specific treatment. There 
are a number of viruses associated with AFM including polio, enterovirus A71, and 
flaviviruses.1–3 The European region was declared polio-free in 2002.4,5 Enterovirus A71 has 
been linked with outbreaks of AFM recently.6,7 Other non-polio enteroviruses have also been 
associated with AFM but more recently cases of AFM associated with Enterovirus D68 (EV-
D68) have been reported.8–11
Since its discovery in 1962, EV-D68 has been associated with sporadic cases of 
respiratory disease and minor outbreaks worldwide.12 However, in 2014, the USA declared a 
nationwide outbreak and reported cases worldwide of over 2000 confirmed cases of EV-
D68.10,13 There was an increased incidence of AFM during these EV-D68 outbreaks and the 
evidence for causality has increased significantly.9,14,15 In the UK, a cluster of neurological illness 
associated with EV-D68 was reported in South Wales in 2016.11 There is a paucity of 
information available about the long-term prognosis and recovery from AFM associated with EV-
D68 infection. 
We report a cluster of AFM associated with EV-D68 in children with their clinical 
presentations, public health investigations, diagnosis, management, and outcome at 18 months. 
This case series will strengthen the existing literature; the clinical outcome at 18 months could 
help clinicians and families to target interventions.
METHOD
After one case of AFM associated with EV-D68 infection presented to the Royal Hospital for 
Sick Children Edinburgh on September 10th, 2016, a multidisciplinary incident management 
team was convened to investigate and set up monitoring for further possible cases. A clinical 
alert was sent to paediatric services throughout Scotland to be aware of potential cases of AFM 
associated with EV-D68 infection and to report all possible cases to the incident management 
team.
The following case definitions for AFM associated with EV-D68 infection were used for 
identifying subsequent cases after September 10th, 2016. 
Possible Case: Person presenting with AFM in Scotland from September 10th, 2016 
without other identified cause.
Confirmed Case: Person presenting with AFM in Scotland from September 10th, 2016 
with laboratory confirmed EV-D68 
Parents of cases were interviewed using a trawling questionnaire (Appendix S2, online 
supporting information) based on recall and covered exposures within 4 weeks before onset of 
Commented [SF1]:  Typesetter: Head A
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symptoms. All confirmed cases were managed by paediatric neurology and intensive care 
specialists at the Royal Hospital for Sick Children Edinburgh. 
Clinical investigations included brain and spine magnetic resonance imaging (MRI), 
electrophysiological studies, cerebrospinal fluid analysis, and virology testing (stool samples, 
throat swabs and nasopharyngeal aspirates [NPA] for a panel of viruses including EV-D6) using 
real time polymerase chain reaction. Stool specimens were all tested for the presence of polio 
virus. Fairly extensive neuroinflammatory investigations were carried out in the first two cases 
and not done in subsequent cases as the diagnosis became more apparent. 
All children were regularly followed up by paediatric neurology, respiratory, 
physiotherapy, occupational therapy, speech and language therapy, psychology, and dietetic 
teams over the following 18 months. Data on this follow-up period were extracted from clinical 
records. 
Parents gave written consent for the use of anonymised data for investigation and 
dissemination. NHS Lothian Caldicott Guardian’s approval was obtained for data storage and 
dissemination.
RESULTS
Clinical presentation and epidemiology
All confirmed cases were residents within the South East Scotland region. Figure 1 displays the 
chronology of onset of prodromal and neurological symptoms for this cluster. From the 
questionnaires, there were no common sources (food, environmental exposures, recent travel, 
and previous direct contact with each other) identified. All children had received age-appropriate 
vaccinations, including inactivated polio vaccine. Their prodromal illness, clinical presentation, 
neurological weakness, investigations, treatment, and progress have been detailed in Table I. 
All presented with asymmetric flaccid weakness of varying severity, severe pain, three with 
bulbar involvement, and the two severely affected cases required intubation and respiratory 
support.
Investigations
All confirmed cases had EV-D68 detected from NPA samples after their admission. Two tested 
positive for EV-D68 on throat swab. However, in one case repeated throat swabs were negative 
and only confirmed on NPA. Viral typing confirmed EV-D68 B3 lineage. Faecal testing for polio 
was negative in all cases.
All children had a brain and spinal MRI and demonstrated an abnormal high T2 signal in the 
spinal cord grey matter (Fig. 2). Three of these cases showed high T2 signal particularly in the 
cervical spinal cord, with one case having entire cord involvement. Four of the children also 
showed signal abnormality in the dorsal pons and medulla. Cerebrospinal fluid results showed 
an elevated white cell count with a predominantly lymphocytic picture, negative for EV-D68 and 
negative for other viruses or bacteria. 
Commented [SF2]:  Typesetter: Head A
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Treatment
One case did not receive any treatment other than supportive care and made excellent 
recovery. No significant improvement in clinical symptoms were observed after use of any 
treatment. Treatment with antihypertensives was commenced in the two most severely affected 
cases to control hypertension. All five children required significant input from a multidisciplinary 
therapy team to manage limb and truncal weakness. Gabapentin was used to control pain with 
good effect. Clinical psychologists were involved in supporting the children and their families.
Clinical outcome at 18 months
Clinical progress at 18 months post admission is summarized in Table I. Recovery for affected 
cases was most significant in the first 12 months; however, they continued to show 
improvement even beyond this time. One child had recovered almost fully with only mild lower 
limb weakness and a mild gait abnormality persisting. Two of the most severely affected 
required long-term home ventilation and were able to manage short periods without ventilation 
during the day while awake. Both children can feed orally with varying degrees of improvement 
in bulbar function. The autonomic dysfunction suffered during the early part of their admission 
resolved fully and antihypertensive therapy stopped. Limb pain lasted 6 months.
Persisting limb weakness and loss of function was predominantly in the lower limbs for 
two children and in the upper limbs for three children. Despite improvements, there has been 
persisting proximal limb weakness with muscle wasting in one or more proximal limbs in all 
cases apart from one. These four cases have been referred for evaluation for nerve transfer. 
We could not reliably use any standardized functional scoring system because of their unique 
pattern of weakness and adaptation. Unlike other motor disorders there seems to be persisting 
regeneration in some muscle groups.
DISCUSSION
The confirmed cases in this cluster were linked in time, place, and person and presented to 
hospital with significant neurological symptoms within a 2-week period. No clear hypothesis for 
a common environmental exposure was identified in this cluster based on recall of parents or 
guardians. After the presentation of this cluster we retrospectively retested all throat swabs and 
NPAs for EV-D68 which had previously tested positive for enterovirus. This retrospective testing 
found 59 samples between July and October 2016 were positive for EV-D68. These were in a 
select population of those presenting to hospital, mostly children with respiratory symptoms; 
however, these positive samples indicate wider circulation of EV-D68 in South East Scotland 
during this time. The baseline clinical data of those children reported to have EV-D68 without 
AFM did not identify any potential risk factors for AFM apart from the fact that the AFM cohort 
were much younger.
The age of presentation, pattern of limb weakness, bulbar involvement, cerebrospinal 
fluid results, MRI findings, and nerve conduction studies are like other reported case series.8–
11,13 Two cases with autonomic involvement with severe hypertension and evidence of end 
organ damage during acute presentation had not been reported before. There was no 
Commented [SF7]:  Typesetter: Head B
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association between steroid treatment and subsequent hypertension. One case developed 
worsening respiratory function after the use of general anaesthetic during lumbar puncture. It is 
not possible to determine whether this was exacerbated by use of anaesthesia, but we advise 
caution with use of general anaesthetic for suspected cases in future. We wanted to carry out 
follow-up MRI studies and we delayed this to avoid general anaesthesia. NPA was found to be 
the investigation which most consistently identified EV-D68 infection even when the throat swab 
was negative. 
Different treatments (intravenous immunoglobulin, steroids, etc.) have been used in 
acute settings and the benefits of these treatments are not well understood. Although the 
numbers are small one case in our cohort made almost full recovery without any treatment. 
Further studies are needed to establish the benefits of these treatments.
Long-term outcome is variable and in our cohort all children can walk, talk, and feed with 
varying degrees of persistent neurological deficits at 18 months follow-up. Permanent proximal 
limb weakness with muscle wasting was present in four cases with varying severity. There 
seems to be continued improvement even at 18 months and rehabilitation in community settings 
with psychological support should be provided for future affected cases.
Recent developments have shown that infection with EV-D68 can cause AFM in murine 
models and the virus has been isolated from the spinal cord of infected mice.13 The short 
duration of prodromal illnesses before onset of acute neurology favours pathogenesis through 
direct destruction of the nerve by the virus. Direct or indirect association of viruses with 
neuroinflammatory disorders (N-methyl-D-aspartate, multiple sclerosis, Guillain-Barré 
syndrome, etc.) are rare but have been increasingly recognized. It is important to try to 
understand the susceptibility in those affected. This is a case series and hence there are 
limitations. There is an urgent need for a coordinated, cooperative, international approach to 
monitoring this emerging infection globally particularly as cases of AFM associated with EV-D68 
infection emerge in other regions out with North America and Europe.16–18
CONCLUSIONS
EV-D68 associated AFM present with short prodromal illness, asymmetric limb weakness, 
bulbar involvement, severe pain, and some autonomic involvement in previously well children, 
confirmed by MRI and EV-68 viral isolation. This condition has a devastating effect on the 
physical and mental health of the child and family and there is a lack of any prevention or 
treatment for complications. There are significant resource implications for health care services; 
not only in the provision of intensive care but also for long-term home ventilation and community 
rehabilitation. Further research should be targeted at the prevention of infection as well as 
understanding and preventing serious sequelae of AFM aiming to minimize complications. To 
achieve these goals, a global coordinated response from researchers, clinicians, virologists, and 
public health is required to understand and ultimately prevent this infection and its potential 
severe neurological sequelae. It is imperative that we act now as outbreaks of EV-D68 and 
reports of cases of AFM associated with infection become more common.
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SUPPORTING INFORMATION
The following additional material may be found online:
Appendix S1: NHS Lothian EV-D68 associated AFM study group.
Appendix S2: Parent interview trawling questionnaire.
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Table I: Characteristics of confirmed cases of EV-D68 with associated AFM and clinical features at 18 
months follow-up
Clinical details Case 1 Case 2 Case 3 Case 4  Case 5
Age at onset 2y 5y 4y 6y 2y
Sex Male Male Female Female Male
Medical history Mild asthma None None None CMPI
Prodromal 
symptoms 
(duration in days)
Fever, 
earache, 
reduced 
appetite (5)
Fever, 
headache, 
malaise, 
pyrexia (4)
Fever, 
headache, 
vomiting (2)
Fever, cough, 
headache, 
reduced 
appetite (1)
Fever, coryza 
(7)
Asymmetric 
severe flaccid 
limb weakness 
Yes Yes Yes Yes Yes 
Limb weakness UL>LL LL>UL UL>LL UL>LL LL>UL
Cranial nerve 
involvement
Yes No Yes Yes Yes 
Bulbar symptoms Yes No Yes Yes No 
Reduced or 
absent reflexes 
Yes Yes Yes Yes Yes 
Autonomic 
symptoms
Yes No No Yes No 
Severe pain Yes Yes Yes Yes Yes 
MRI cord 
abnormality 
(location)
Yes (C2–C7) Yes (C2–C7) Yes 
(movement 
artefact)
Yes (C2–C7) Yes (entire 
cord, 
maximum 
T1–T2)
MRI abnormality 
of pons and 
medulla
Yes No No Yes Yes
EV-D68 
polymerase 
chain reaction 
detection
NPA (+)
Throat swab (-)
CSF (-)
Stool (-)
NPA (+) 
Throat swab (-)
Stool (-)
NPA (+)
Throat swab 
(-)
Stool (-)
NPA (+)
Throat swab (+)
Stool (-)
NPA (+)
Throat swab 
(+)
CSF (-)
Stool (-)
Electromyography Increased Not Not Increased Not 
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(left biceps) insertional 
activity, 
frequent 
fibrillations. No 
voluntary 
activity
performed performed insertional 
activity, 
widespread 
fibrillations. 
Two discrete 
complex 
repetitive 
discharges. 
No 
spontaneous 
activity
performed
Nerve conduction 
studies
Normal 
sensory
Reduced 
CMAP
Not 
performed
Not 
performed
Normal 
sensory
Early CMAP 
normal
Not 
performed
Treatment IVIG, Steroids None IVIG IVIG IVIG, steroids
Respiratory 
support
Yes (long-term 
invasive 
ventilation)
No No Yes (long-term 
invasive 
ventilation)
No
Intensive care 
support
Prolonged No No Prolonged Short term
Hospital stay 
(days)
376 67 125 278 62
At 18mo follow-up
Mobility Walking short 
distances 
Walking short 
distances. 
Almost 
normal 
mobility. 
Walking short 
distances.
Almost 
normal 
mobility.
Speech Normal Normal Normal Almost normal Normal
Swallow Normal Normal Normal Almost normal Normal
Weakness Significant 
proximal upper 
limb 
(asymmetric) 
with muscle 
wasting
Significant 
lower limb 
proximal 
weakness 
(asymmetric)
Mild distal 
unilateral 
lower limb 
weakness 
affecting 
gait
Significant 
proximal upper 
limb 
(asymmetric) 
with muscle 
wasting
Significant 
proximal 
upper limb 
(asymmetric) 
with muscle 
wasting
Shoulder 
dislocation
Yes No No Yes Yes
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Scoliosis Yes Yes No Yes No 
Head tilt Yes No No Yes Yes 
Breathing Tracheostomy 
and ventilatory 
support during 
sleep
Normal Normal Tracheostomy 
and ventilatory 
support during 
sleep
Normal 
EV-D68, enterovirus D68; AFM, acute flaccid myelitis; CMPI, cow’s milk protein intolerance; UL, 
upper limb; LL, lower limb; MRI, magnetic resonance imaging; NPA, nasopharyngeal aspirate; 
CSF, cerebrospinal fluid; CMAP, compound muscle action potential; IVIg, intravenous 
immunoglobulin.
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[Figure legends]
Figure 1: Timeline of symptom onset or confirmed cases of acute flaccid myelitis associated with 
enterovirus D68 infection
Figure 2: Magnetic resonance imaging (MRI) of the spinal cord and brainstem in acute flaccid myelitis 
caused by enterovirus D68. The saggital T2-weighted sequences (a,d) showing longitudinal hyperintense 
signal and the Axial T2-weighted sequences (b,c) showing hyperintensity in spinal cord grey matter (b) 
and dorsal brainstem (c).
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(a) 
(b) 
(d) 
Magnetic	resonance	imaging	(MRI)	of	the	spinal	cord	and	brainstem	in	acute	flaccid	myelitis	caused	by	
enterovirus	D68.	The	saggital	T2-weighted	sequences	(a,d)	showing	longitudinal	hyperintense	signal	and	the	
Axial	T2-weighted	sequences	(b,c)	showing	hyperintensity	in	spinal	cord	grey	matter	(b)	and	dorsal	brainstem	
(c). 
Figure	2.	MRI	spine	and	brainstem	in	AFM	due	to	EV	D68-	Scotland	 
(c) 
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Case no 
Patient Name__________________________________________________________________DOB__/__/_______ 
 1 
 
NHS Lothian Acute Neurologic Illness with Limb Weakness in Children: Form                   
Form to be completed by or in conjunction with a physician who provided care to the patient during the neurologic illness.                                                
Part 1A Patient details 
1.Today’s date__ __/__ __/__ __ __ __  (dd/mm/yyyy)  2.Name of person completing form: 
______________________________________________  
3. HPT Board ____________________________________ 
4. Name of physician who can provide additional clinical/lab information, if needed 
_____________________________________________________ 
5. Hosp_____________________________________ Phone:  ___________________________ Email: 
______________________________________ 
6. Patient  Name _________________________________________________________________________________________________ 
7. CHI___________________________________________________________________________________________________________ 
8. Patient’s Sex M     F          
9. Patient’s DOB__ __/__ __/__ __ __ __  age: ______years   AND _______months               
10. Patient’s home address ___________________________________________________________________________11. Post code________ 
12. Ethnicity:             Asian/Asian British        Black / African / Caribbean / Black British Mixed / Multiple ethnic groups      White  
12. Date of onset of initial illness __ __/__ __/__ __ __ __ Date of onset of  any  limb weakness:   __ __/__ __/__ __ __ __  arm   /   leg 
Details_______________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________
Past Medical History____________________________________________________________________________________________________ 
13. Was patient admitted to a hospital?   yes      no 
 14. Date of admission to first hospital__ __/__ __/__ __ __ __  Where______________________Date of admission to  RHSC __ __/__ __/__ __  
Details of general ward________________________________  HDU or  ICU admission yes     no   & dates __ __/__ __/__ __ __ __   
Ventilated yes     no         Date ventilation started__ __/__ __/__ __ __ __  Date came off ventilator__ __/__ __/__ __ __ __   
................................................................................................................................………………………………………………………………………………………………….. 
Outcome 
15. Confirmed Enterovirus D68 yes     no  Sample_________________________________________________________________________         
16. Date of discharge from hospital__ __/__ __/__ __ __ __   Discharge to home yes,  another hospital yes  
Details: 
Clinical status two months after onset: At home still in hospital    improved    not improved ventilated     Died: __ __/__ __/__ __ __ 
Comments : 
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PART 1B Epidemiology details completed on __ __/__ __/2016 .Name of Dr completing this bit of the form 
Explain-unusual illness in the UK and we would like to gather more information in order to understand the illness better 
 
Family history:   
Details of who does the case live with (name/age) 
 
 
 
Details of pets in household 
Anyone in the household with similar symptoms of intercurrent illness?  yes  no unknown  add details/dates 
 
 
Details of any contact with anyone else with similar symptoms  
 
 
Details of nursery playgroup childminder school attended 
 
Details of attendance at any health care waiting rooms eg GP, dentist, A&E  
 
Vaccination history:   
Are they up to date according to UK childhood schedule?  yes  no unknown 
44. How many doses of inactivated polio vaccine (IPV) are documented to have been received by  
       the patient before the onset of weakness? & when _______doses           unknown 
45. How many doses of oral polio vaccine (OPV) are documented to have been received by the    
       patient before the onset of weakness? & when _______doses           unknown 
46. If you do not have documentation of the type of polio vaccine received: 
      What is total number of documented polio vaccine doses received before onset of weakness?             _______doses            unknown 
47.  Details of last vaccination received & when?  
48.  Flu vaccine details what when?  
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 3 
TRAVEL IN UK AND ABROAD in 4 weeks pre-onset of limb weakness Yes No NS 
1. Spent any nights away from home WITHIN THE UK? (Holidays or business trips; staying at 
friends or relatives, hotels, campsites, etc) 
   
IF YES: Please state dates and  
where 
From:     /     /        To:   /     /      
Address visited, including 
postcode: 
              
2. Spent any nights away from home OUTSIDE THE UK  (Holidays or business trips; staying at 
friends or relatives, hotels, campsites, etc) 
   
IF YES: Please state dates and 
country/resort 
From:     /     /        To:   /     /      
Country and resort:      
Environmental exposures: in the 4 weeks before onset, has the patient: Yes No  Unk 
Swam or played in a swimming pool, indoor or outdoor? If Yes, details: 
 
   
Taken part in water sports including sailing, canoeing, windsurfing, fishing? If Yes, details: 
 
   
Taken part in any outdoor activity that brought them into contact with forest, soil, mud or water-
courses in fields or open land, including hill-walking, mountain-biking and canoeing? If Yes, 
details: 
 
   
Any insect bites (including tick bites) ? If Yes, details: 
 
   
Worked/played in a garden or allotment (including usual home gardening)? If Yes, details: 
 
   
Used or had contact with any household chemical for cleaning (e.g. bleach, cleaning sprays)? If 
Yes, details: 
 
   
Used or had contact with any garden chemicals, such as weedkillers, insecticides? If Yes, 
details: 
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Food and drink exposures: In the 4 weeks before onset, has the patient: 
Yes No Unk 
Eaten any meals/ snacks bought from fast-food outlets? Fast-food outlets include any restaurant, 
stall or shop where food is paid for before it is eaten, such as sandwich bars, canteens, burger 
bars, kebab shops, fish and chip shows, hot dog stands, food outlets at markets  
   
Eaten any meals or snacks from any other restaurants, cafes, pubs or hotels?    
Eaten any meals or snacks at any function or gathering, e.g. at a party, reception, barbecue, 
picnic, etc?  
   
Eat any meals/snacks bought from grocers, bakers, supermarkets or delicatessens which were 
consumed away from the premises? 
   
Eaten any fish or shellfish?    
Eaten any tinned food?    
Eaten any new, unusual or imported foods? (e.g. wild berries, teas)    
Used any Chinese or herbal medicines etc (details )    
If yes to any of the above, please add details of premises, food items and dates consumed 
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 5 
Places visited or any social gatherings  in 14 days prior to onset of initial illness DOO__/__/_____ 
(Family might want to take this away and complete) 
Day & date Morning Afternoon Evening 
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PART 2 Virology testing:  details completed on __ __/__ __/2016 .Name of Dr completing this bit of the form:  
 
 
73. Was CSF tested for the following 
pathogens? 
Date of specimen collection __ __/__ __/__ __ __ __                               Not done 
  Enterovirus PCR:   Positive      Negative      Not done 
          If positive: type:                                               Not typed   
  Herpes Simplex Virus PCR:     Positive      Negative      Not done     
 Cytomegalovirus PCR:      Positive      Negative      Not done 
 Varicella Zoster Virus PCR:      Positive      Negative      Not done 
 Other pathogen identified:      specify:  
Type of test: 
74. Was a respiratory tract specimen tested 
for the following pathogens? 
Date of specimen collection __ __/__ __/__ __ __ __                            Not done 
 Enterovirus/rhinovirus PCR:   Positive      Negative      Not done 
          If positive: type:                                               Not typed   
 Adenovirus PCR:   Positive      Negative      Not done 
          If positive: type:                                               Not typed   
 Influenza virus PCR:      Positive      Negative      Not done 
          If positive: type:                                               Not typed   
 Other pathogen identified:    specify:  
Type of test:   
75. Was a stool specimen tested for the 
following pathogens? 
Date of specimen collection __ __/__ __/__ __ __ __                                      Not done 
   Enterovirus PCR:   Positive      Negative      Not done 
          If positive: type:                                               Not typed   
 Poliovirus PCR:   Positive      Negative      Not done 
ID ______________ 
Page 4 of 6 
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77. Describe any other laboratory finding(s) considered to be significant_____________________________________________________________ 
 Poliovirus culture:   Positive      Negative      Not done 
 Other pathogen identified: specify:  
Type of test:  
76. Was serum tested for the following 
pathogens? 
Date of specimen collection __ __/__ __/__ __ __ __                                      Not done 
 West Nile Virus:      Positive      Negative      Not done 
          If positive, test type:      IgM       PCR    
 Other pathogen identified: specify:  
Type of test: 
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PART 3 Clinical Neurological details completed on __ __/__ __/2016 .Name of Dr completing this bit of the form:  
 
 
 
 
 
17. Signs/symptoms/condition at ANY time during the illness:  
Date of onset of limb weakness:   __ __/__ __/__ __ __ __   
 Right Arm Left Arm Right Leg Left Leg 
18.  Since neurologic illness onset, which limbs have been acutely weak? 
[indicate yes(y), no (n), unknown (u) for each limb] Y       N       U Y        N       U Y        N       U Y        N       U 
19.  Date of neurologic exam (recorded at worst weakness thus far)  
(dd/mm/yyyy) 
__  __ /__  __/__ __ __ __ 
20.  Reflexes in the affected limb(s): (recorded at worst weakness thus far)     Areflexic/hyporeflexic (0-1)   Normal (2)   Hyperreflexic (3-4+) 
21. Any sensory loss/numbness in the affected limb(s), at any time during 
the illness? (paresthesias should not be considered here) 
Y       N       U 
22. Any pain or burning in the affected limb(s)? (at any time during illness) Y       N       U Y       N       U Y       N       U Y       N       U 
 Yes No  Unknown 
23. Sensory level on the torso (ie, reduced sensation below a certain level of the torso)?  (at any time during illness)     
24. At any time during the illness, please check if the patient had any of the following cranial nerve signs:  
 
              Diplopia/double vision (If yes, circle the cranial nerve involved if known: 3  /  4  /  6 )    
              Loss of sensation in face      Facial droop          Hearing loss         Dysphagia               Dysarthria                     
25. Any pain or burning in neck or back?  (at any time during illness)    
26. Bowel or bladder incontinence?  (at any time during illness)    
27 .Cardiovascular instability (e.g, labile blood pressure, alternating tachy/bradycardia)?  (at any time during illness)    
28. Change in mental status (e.g, confused, disoriented, encephalopathic)?  (at any time during illness)    
29. Seizure(s)?  (at any time during illness)    
30. Received care in ICU because of neurologic condition? (at any time during illness)    
31. Received invasive ventilatory support (e.g, intubation, tracheostomy) because of neurological condition?    
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Within the 4-week period BEFORE onset of 
limb weakness, did patient: Yes No Unkn 
 
          32. Have a respiratory illness?   
 
 
 
 
    
33. If yes, date of onset   __ __/__ __/__ __ __ __   & details of symptoms   
 
          34. Have a fever, measured by parent  
                 or provider and ≥ 38.0°C?       
    
35. If yes, date of onset   __ __/__ __/__ __ __ __     
          36. Receive oral, IM or IV steroids?     
          37. Receive any other systemic  
                Immunosuppressant(s)?    
38. If yes, list: 
               
     
41. Does patient have any underlying illnesses? 
Past Medical History 
   
42. If yes, list 
 
 
43. On the day of onset of limb weakness, did      
      patient have a fever? (see definition above)    
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Neuroradiographic findings: (Indicate based on most abnormal study)  
MRI of spinal cord                47. Date of study __ __/__ __/__ __ __ __   (mm/dd/yyyy)   
48. Levels imaged:                 cervical     thoracic    lumbosacral    unknown                   
49. Gadolinium used?           yes             no              unknown      
 
MRI of brain                            62. Date of study __ __/__ __/__ __ __ __   (dd/mm/yyyy) 
58. Gadolinium used?             yes         no         unknown       
 
69. Was an EMG done?         yes         no         unknown      If yes, date  __ __/__ __/__ __ __ __    (mm/dd/yyyy)   
70. If yes, was there evidence of acute motor neuropathy, motor neuronopathy, motor nerve or anterior horn cell involvement?yes   no  unkn      
 
 
50. Location of lesions: 
cervical cord         thoracic cord        
conus                     cauda equina     
unknown 
Levels of cord affected (if applicable): 
 
51. Cervical: _________                    52. Thoracic: _________ 
For cervical and thoracic 
cord lesions 
53. What areas of spinal cord      
       were affected? predominantly gray matter                predominantly white matter                     
both equally affected                          unknown 
 
54. Was there cord edema? yes         no         unknown       
 
  
For cervical, thoracic cord 
or conus lesions 
55. Did any lesions enhance with     
      GAD? 
yes         no         unknown       
 
  
For cauda equina lesions 56. Did the ventral nerve roots     
       enhance with GAD? 
yes         no       unknown      
 57. Did the dorsal nerve roots  
       enhance with GAD? 
yes         no       unknown      
59. Any supratentorial (i.e, lobe, 
cortical, subcortical, basal ganglia, 
or thalamic) lesions 
yes     no       unknown       
 
60.If yes, indicate location(s)  cortex        subcortex      basal ganglia            thalamus           unknown 
 61. If yes, did any lesions  
      enhance with GAD? 
yes         no         unknown       
62. Any brainstem lesions?  yes     no       unknown       
 
63. If yes, indicate location:  midbrain        pons           medulla             unknown 
 64. If yes, did any lesions  
      enhance with GAD? 
yes         no         unknown       
65. Any cranial nerve lesions? yes     no       unknown       
 66. If yes, indicate which     
       CN(s): CN_____ unilateral   bilateral            CN_____ unilateral   bilateral     
  CN_____ unilateral   bilateral            CN_____ unilateral   bilateral     
 67. If yes, did any lesions    
       enhance with GAD? yes         no         unknown       
68. Any lesions affecting the         
      cerebellum? 
yes     no       unknown      
 
ID ______________ 
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CSF examination: 71. Was a lumbar puncture performed?   yes       no      unknown   If yes, complete 72 (If more than 2 CSF examinations, list 
earliest and then most abnormal)   
71. Any other significant details of clinical illness? 
 Date of lumbar 
puncture WBC/mm3 
% 
neutrophils 
% 
lymphocytes 
%         
monocytes 
% 
eosinophils RBC/mm3 Glucose mg/dl Protein  mg/dl 
72a. CSF 
from LP1 
 
 
            
 
 
72b. CSF 
from LP2 
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